128 related articles for article (PubMed ID: 17012895)
1. Applications of influenza virosomes as a delivery system.
Cusi MG
Hum Vaccin; 2006; 2(1):1-7. PubMed ID: 17012895
[TBL] [Abstract][Full Text] [Related]
2. Virosomes for antigen and DNA delivery.
Daemen T; de Mare A; Bungener L; de Jonge J; Huckriede A; Wilschut J
Adv Drug Deliv Rev; 2005 Jan; 57(3):451-63. PubMed ID: 15560951
[TBL] [Abstract][Full Text] [Related]
3. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination.
Jamali A; Holtrop M; de Haan A; Hashemi H; Shenagari M; Memarnejadian A; Roohvand F; Sabahi F; Kheiri MT; Huckriede A
Immunol Lett; 2012; 148(1):77-82. PubMed ID: 22981929
[TBL] [Abstract][Full Text] [Related]
4. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.
Glück R; Moser C; Metcalfe IC
Expert Opin Biol Ther; 2004 Jul; 4(7):1139-45. PubMed ID: 15268680
[TBL] [Abstract][Full Text] [Related]
5. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses.
Kammer AR; Amacker M; Rasi S; Westerfeld N; Gremion C; Neuhaus D; Zurbriggen R
Vaccine; 2007 Oct; 25(41):7065-74. PubMed ID: 17766014
[TBL] [Abstract][Full Text] [Related]
6. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial.
Adamina M; Weber WP; Rosenthal R; Schumacher R; Zajac P; Guller U; Frey DM; Oertli D; Zuber M; Heberer M; Spagnoli GC
Contemp Clin Trials; 2008 Mar; 29(2):165-81. PubMed ID: 17707139
[TBL] [Abstract][Full Text] [Related]
7. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.
Bungener L; Huckriede A; de Mare A; de Vries-Idema J; Wilschut J; Daemen T
Vaccine; 2005 Jan; 23(10):1232-41. PubMed ID: 15652665
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant and antigen delivery properties of virosomes.
Glück R; Burri KG; Metcalfe I
Curr Drug Deliv; 2005 Oct; 2(4):395-400. PubMed ID: 16305442
[TBL] [Abstract][Full Text] [Related]
9. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells.
Angel J; Chaperot L; Molens JP; Mezin P; Amacker M; Zurbriggen R; Grichine A; Plumas J
Vaccine; 2007 May; 25(19):3913-21. PubMed ID: 17336432
[TBL] [Abstract][Full Text] [Related]
10. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes.
Cusi MG; Terrosi C; Savellini GG; Di Genova G; Zurbriggen R; Correale P
Vaccine; 2004 Jan; 22(5-6):735-9. PubMed ID: 14741166
[TBL] [Abstract][Full Text] [Related]
11. The effect of pre-existing immunity on the capacity of influenza virosomes to induce cytotoxic T lymphocyte activity.
de Mare A; Bungener LB; Regts J; de Vries-Idema J; van der Zee AG; Wilschut J; Daemen T
Vaccine; 2008 May; 26(19):2314-21. PubMed ID: 18400343
[TBL] [Abstract][Full Text] [Related]
12. Virosome: An engineered virus for vaccine delivery.
Ali H; Akbar M; Iqbal B; Ali F; Sharma NK; Kumar N; Najmi A; Albratty M; Alhazmi HA; Madkhali OA; Zoghebi K; Alam MS
Saudi Pharm J; 2023 May; 31(5):752-764. PubMed ID: 37181145
[No Abstract] [Full Text] [Related]
13. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs.
Felnerova D; Viret JF; Glück R; Moser C
Curr Opin Biotechnol; 2004 Dec; 15(6):518-29. PubMed ID: 15560978
[TBL] [Abstract][Full Text] [Related]
14. Influenza virosomes in vaccine development.
Huckriede A; Bungener L; Daemen T; Wilschut J
Methods Enzymol; 2003; 373():74-91. PubMed ID: 14714397
[TBL] [Abstract][Full Text] [Related]
15. Modified influenza virosomes: recent advances and potential in gene delivery.
Khoshnejad M; Young PR; Toth I; Minchin RF
Curr Med Chem; 2007; 14(29):3152-6. PubMed ID: 18220748
[TBL] [Abstract][Full Text] [Related]
16. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells.
Amacker M; Engler O; Kammer AR; Vadrucci S; Oberholzer D; Cerny A; Zurbriggen R
Int Immunol; 2005 Jun; 17(6):695-704. PubMed ID: 15843436
[TBL] [Abstract][Full Text] [Related]
17. The virosome concept for influenza vaccines.
Huckriede A; Bungener L; Stegmann T; Daemen T; Medema J; Palache AM; Wilschut J
Vaccine; 2005 Jul; 23 Suppl 1():S26-38. PubMed ID: 16026906
[TBL] [Abstract][Full Text] [Related]
18. Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment.
Liu H; Tu Z; Feng F; Shi H; Chen K; Xu X
Acta Pharm; 2015 Jun; 65(2):105-16. PubMed ID: 26011928
[TBL] [Abstract][Full Text] [Related]
19. Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine.
Dong W; Bhide Y; Marsman S; Holtrop M; Meijerhof T; de Vries-Idema J; de Haan A; Huckriede A
Biotechnol J; 2018 Apr; 13(4):e1700645. PubMed ID: 29278302
[TBL] [Abstract][Full Text] [Related]
20. Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system.
Cryz SJ; Glück R
Dev Biol Stand; 1998; 92():219-23. PubMed ID: 9554278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
